Ibima Bionand Platform researchers (Malaga Biomedical Research Institute and Platform in Nanomedicin (Ibima Bionand Platform) have participated in a reference article … Posted in Allergy
The inhaled prolonged muscarinic antagonists (LAMA) were initially developed to treat chronic obstructive pulmonary disease (COPD). However, recent evidence has also demonstrated its effectiveness in asthmatic patients, by reducing serious exacerbations and improving lung function.
“We are facing an important advance that will improve the therapeutic approach in people with asthma that fail to properly control their disease with the usual treatments,” says Dr. Ibon Eguíluz, principal author of the article and researcher of the group “Allergic diseases to drugs and allergens” of Ibima Bionand platform, led by Dr. María José Torres Jaén. “The use of lama in asthma remains an emerging field, but with great clinical projection,” he adds.
One of the main current challenges is to accurately define the patient profile that can benefit more from this therapeutic option and establish its place within the integral management of asthma. The work led by Ibima Bionand has focused on identifying these key characteristics and proposing a prescription protocol that optimizes its use.
Advances in asthma knowledge
Dr. Eguíluz explains that «after years of collaboration, we have managed to agree on a set of clinical criteria that allow the indication of the LAMA in asthma with greater security and effectiveness. We hope this contributes to improving the quality of life of many patients who do not respond well to conventional therapies ».
-The study has also revealed anti -inflammatory properties of LAMA, until now little valued in the context of asthma. It has been proven that these drugs reduce the presence of leukocytes in the bronchial tissue, which is a new perspective on its mechanism of action and suggests additional benefits in patients with a marked inflammatory component.
The research has been coordinated by Dr. Eguíluz with the participation of International experts in pneumology, allergology, pharmacology, pediatrics and basic research. Among the co -authors are doctors Guillermo Bentabol (HRUM Pneumology UGC), María José Torres and Almudena Testera (HRUM allergology UGC).
“International collaboration has been fundamental to provide the study of the necessary rigor and depth,” says Dr. Almudena Testera. “We believe that our findings can guide clinical practice and open new lines of research on the use of these drugs in asthma.”
Practical and future implications lines of work
This study marks a significant step towards a more adjusted approach to the individual characteristics of each asthmatic patient. The ability to better select the appropriate candidates for LAMA therapy could reduce the number of therapeutic failures and optimize the resources of the health system.
“The true contribution of this work is that it helps us to refine the treatment based on the specific needs of each patient,” says Dr. María José Torres. In addition, it is already proposed to deepen the study of biomarkers that facilitate the identification of suitable patients and explore in greater depth the anti -inflammatory properties of LAMA.
